Table 4.
Risk factors for IBD remission if active IBD at cancer diagnosis.
| Variable | Bivariate Hazard Ratio (95% CI) |
|---|---|
| IBD Subtype | |
| Crohn’s disease | Reference |
| Ulcerative colitis | 1.58 (0.55–4.60) |
| Indeterminate colitis | - |
| Sex | |
| Female | Reference |
| Male | 0.55 (0.15–1.97) |
| Race/Ethnicity | |
| White | Reference |
| Black | 2.30 (0.51–10.4) |
| Hispanic | - |
| Asian | 3.11 (0.39–25.1) |
| Unknown | - |
| Age at IBD diagnosis | 1.04 (0.99–1.09) |
| Smoking history at cancer diagnosis | |
| Never | Reference |
| Former | 1.43 (0.48–4.26) |
| Current | 6.14 (0.65–58.0) |
| Primary sclerosing cholangitis | - |
| IBD treatment before cancer | |
| 5-ASA | 0.81 (0.22–2.93) |
| Steroids | 0.91 (0.32–2.59) |
| Immunomodulators | 0.62 (0.17–2.21) |
| Biologics | 0.04 (0.00–14.5) |
| Previous surgery for IBD | 0.58 (0.18–1.86) |
| Type of Cancer | |
| Breast | Reference |
| Prostate | 0.34 (0.08–1.52) |
| Age at cancer diagnosis | 1.04 (0.98–1.10) |
| Stage | |
| I | 1.39 (0.41–4.74) |
| II | 1.92 (0.35–10.5) |
| III | 1.13 (0.13–10.2) |
| IV | Reference |
| Unknown | - |
| Immunomodulators or biologics discontinued for cancer | 0.98 (0.09–10.90) |
| Cancer treatment | |
| Surgery | 26.5 (0.54–1290) |
| Radiotherapy | 1.53 (0.43–5.50) |
| Cytotoxic chemotherapy only | - |
| Hormone therapy only | 1.98 (0.42–9.34) |
| Cytotoxic chemotherapy and hormone therapy | 2.09 (0.35–12.5) |
| Neither cytotoxic nor hormone therapy | Reference |